References
- Koo J. Population‐based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996; 14: 485–96
- Rapp S. R., Exum M. L., Reboussin D. M., Feldman S. R., Fleischer A., Clark A. R. The physical, psychological and social impact of psoriasis. J Health Psychol 1997; 2: 525–37
- Lebwohl M., Sherer D., Washenik K., Krueger G. G., Menter A., Koo J. A randomized, double‐blind, placebo‐controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol 2002; 41: 269–74
- Rapp S. R., Feldman S. R., Fleischer A. B Jr., Reboussin D. M., Exum M. L. Health related quality of life in psoriasis: a biopsychosocial model and measures. Care management of skin diseases: life quality and economic impact, R Rajagopalan, E. F Sheretz, R Anderson. Marcel Dekker, New York 1998; 125–45
- Arruda L. H., De Moraes A. P. The impact of psoriasis on quality of life. Br J Dermatol 2001; 144((Suppl 58))33–6
- Al Suwaidan S. N., Feldman S. R. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol 2000; 42: 796–802
- Housman T. S., Mellen B. G., Rapp S. R., Fleischer A. B Jr., Feldman S. R. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis 2002; 70: 327–32
- Amin S., Cornell R., Soughton R., Maibach H. In: Psoriasis, 3rd edn, , et al. Marcel Dekker, New York 1998; 453–67
- Katz H. I., Ngo T. H., Prawer S. E., Mastbaum L. I., Mooney J. J., Samson C. R. Superpotents steroid treatment of psoriasis vulgaris – clinical efficacy and adrenal function. J Am Acad Dermatol 1987; 16: 804–11
- Feldman S. R., Housman T. S. Patients' vehicle preference for corticosteroid treatments of severe psoriasis. Am J Clin Dermatol 2003; 4: 221–4
- Bergstrom K. G., Arambula K., Kimball A. B. Medication formulation affects quality of life: a randomized single‐blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis 2003; 72: 407–11
- Decroix J., Pres H., Tsankov N., Poncet M., Arsonnaud S. Clobetasol propionate lotion in the treatment of moderate to severe plaque‐type psoriasis. Cutis 2004; 74: 201–6